SAN DIEGOandSTOCKHOLM, Sweden, June 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento")today announced that the Company has entered into an additional collaborative agreement with NextGenNK Competence Center-associated research groups at the Department of Medicine, Huddinge, KarolinskaInstitutet(KI) inStockholm, Sweden, aimed at producing novelcell-based therapeutics using natural killer (NK) cells derived from induced pluripotent stem cells (iPSCs).
Global Autologous Stem Cell and Non-Stem Cell Based Therapies Marketresearch report has set a bench-marking example for such a vibrant market that explores several recommendations and practical growth strategies in relation to the market. The chapter on the competitive landscape is presented well in the research report and is analyzed based on the tools such as Porters five forces analysis. This market research document produced covers numerous growth prospects in recent times with linkage in the coming decades
The acquisition provides the companies with shared scientific knowledge and resources leading to a stronger foundation for advancing newborn stem cell research TORONTO, June 2, 2021 /CNW/ -- The Cell Care international umbilical cord blood and tissue banking group, which incorporates Insception Biosciences Inc. (Insception) in Canada, today announced that it has been acquired by Generate Life Sciences (Generate).* Generate operates Cord Blood Registry (CBR), North America's largest cord blood bank and one of the world's preeminent stem cell R&D organizations. Insception joins CBR to create a unique, international scientific collaboration to further newborn stem cell and regenerative medicine research.
Therapy with Blincyto (blinatumomab), a CD19 BiTE (bispecific T-cell engager), demonstrated a longer survival time for patients with relapsed/refractory acute lymphoblastic leukemia, according to data published in Cancer. Allogenic hematopoietic stem cell transplantation was typically viewed as the only curative option for patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia, according to the studys introduction. Blincyto has previously been shown to be a potential therapy with long-term survival benefit even without hematopoietic stem cell transplantation
Karen Hasty, PhD, a professor, researcher, and director of Basic Research in the Department of Orthopaedic Surgery and Biomedical Engineering/Campbell Clinic in the College of Medicine at the University of Tennessee Health Science Center, has been named among the 2021 Super Women in Business by the Memphis Business Journal. The annual list honors women business leaders for their career accomplishments and work in the Memphis community.
Apart from culture media, surface coatings, and pluripotency level of the cells you work with, the cell density is the fourth major contributor to experimental success. Intercellular signaling is difficult to control, but seeding cells at the right concentration can significantly contribute towards getting the directed differentiation of interest
Hundreds of U.S. stem cell clinics selling experimental therapies without an FDA permit can expect to face the agencys enforcement arm and potential action from the federal government
As expected, the International Society for Stem Cell Research (ISSCR) has updated its guidelines for stem cell research. The marquee guideline is the relaxation of the limit of 14 days on how long a human embryo may be kept alive in a lab. According to the ISSCR the update reflects emerging advances including stem cell-based embryo models, human embryo research, chimeras, organoids, genome editing and ectogenesis.
Deafness is the most common sensory impairment in newborn children about 1 child in 1000 is born with hearing loss, or develops it in early childhood.Half of these cases have a genetic cause; very often, this type of deafness is related to a mutation of a gene called 'gap junction beta 2 (GJB2)', which encodes a protein called 'connexin 26 (CX26)'. This protein occurs in cells in the cochlea, the part of the inner ear enabling hearing. One way of treating GJB2-related deafness would be to reproduce properly functioning cochlear cells and introduce them into the inner ear
Limit on lab-grown human embryos dropped by stem-cell body Nature.com Human Stem Cell Research Guidelines Updated The Scientist Stem cell guidelines open door to more permissive research on human embryos Science Magazine New global guidelines for stem cell research aim to drive discussions, not lay down the law The Conversation AU Citing stem cell advances, ISSCR extends permissible limit on human embryo research BioWorld Online View Full Coverage on Google News
Recent Comments